董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Richard T. LeBuhn | 男 | Director | 61 | 未披露 | 2.97 | 2026-02-04 |
| Louis E. Silverman | 男 | Independent Director | 67 | 25.48万美元 | 1.36 | 2026-02-04 |
| Arthur C. Butcher | -- | Independent Director | -- | 24.34万美元 | 2.44 | 2026-02-04 |
| Wei Jiang | -- | Independent Director | -- | 153.60万美元 | 8.22 | 2026-02-04 |
| Lilian Zhou | -- | Independent Director | -- | 44.86万美元 | 3.40 | 2026-02-04 |
| Christopher Min Fang Wang | 男 | Director | 54 | 未披露 | 326.47 | 2026-02-04 |
| Neal C. Bradsher | 男 | Board Chair | 60 | 未披露 | 1615.73 | 2026-02-04 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Warren Foust | -- | Interim Co-Chief Executive Officer,President and Chief Operating Officer | -- | 444.07万美元 | 15.06 | 2026-02-04 |
| Magda Michna | -- | Chief Development Officer | -- | 269.58万美元 | 8.79 | 2026-02-04 |
| Deborah Andrews | 女 | Chief Financial Officer and Interim Co-Chief Executive Officer | 68 | 258.24万美元 | 2.43 | 2026-02-04 |
董事简历
中英对照 | 中文 | 英文- Richard T. LeBuhn
-
Richard T. LeBuhn，2006年6月起，担任Broadwood Capital, Inc的高级副总裁，这是Broadwood Partners, L.P.的投资管理人。此前，2005-2006，他是私募投资公司Broadfield Capital Management, LLC的合伙人；2002年7月至2005年5月，担任私募投资公司Derchin Management的副总裁。职业生涯早期，他曾创办投资分析与金融顾问公司Triple Eight Capital, LLC，并担任其管理合伙人，曾担任私募投资公司Craig Drill Capital的董事总经理，以及Chubb and Son, Inc的运营业务经理，这是The Chubb Corporation的财产与意外险业务分部。1996年，他在获得金融方向的工商管理硕士学位；1988年，在St. Lawrence University获得经济学士学位。他现为Comarco, Inc的董事。
Richard T. LeBuhn joined the Board in April 2014. He serves as Chairman of the company’s Audit Committee and Nominating and Corporate Governance Committee and is a member of the company’s Compensation Committee. Since June 2006 he is Senior Vice President at Broadwood Capital, Inc., the investment manager of Broadwood Partners, L.P. Previously, Mr. LeBuhn was Principal of Broadfield Capital Management, LLC, a private investment firm, from 2005 to 2006 and Vice President of Derchin Management, a private investment firm, from July 2002 to May 2005. Earlier in his career, Mr. LeBuhn founded and was Managing Member of Triple Eight Capital, LLC, an investment analysis and financial advisory firm, was Managing Director of Craig Drill Capital, Inc., a private investment firm, and served as an operating business manager for Chubb and Son, Inc., the property and casualty insurance division of The Chubb Corporation. Mr. LeBuhn received a M.B.A. in Finance with Distinction from Columbia University Graduate School of Business in 1996. He received a B.A. in Economics from St. Lawrence University in 1988. Mr. LeBuhn currently serves as a director of Comarco, Inc. - Richard T. LeBuhn，2006年6月起，担任Broadwood Capital, Inc的高级副总裁，这是Broadwood Partners, L.P.的投资管理人。此前，2005-2006，他是私募投资公司Broadfield Capital Management, LLC的合伙人；2002年7月至2005年5月，担任私募投资公司Derchin Management的副总裁。职业生涯早期，他曾创办投资分析与金融顾问公司Triple Eight Capital, LLC，并担任其管理合伙人，曾担任私募投资公司Craig Drill Capital的董事总经理，以及Chubb and Son, Inc的运营业务经理，这是The Chubb Corporation的财产与意外险业务分部。1996年，他在获得金融方向的工商管理硕士学位；1988年，在St. Lawrence University获得经济学士学位。他现为Comarco, Inc的董事。
- Richard T. LeBuhn joined the Board in April 2014. He serves as Chairman of the company’s Audit Committee and Nominating and Corporate Governance Committee and is a member of the company’s Compensation Committee. Since June 2006 he is Senior Vice President at Broadwood Capital, Inc., the investment manager of Broadwood Partners, L.P. Previously, Mr. LeBuhn was Principal of Broadfield Capital Management, LLC, a private investment firm, from 2005 to 2006 and Vice President of Derchin Management, a private investment firm, from July 2002 to May 2005. Earlier in his career, Mr. LeBuhn founded and was Managing Member of Triple Eight Capital, LLC, an investment analysis and financial advisory firm, was Managing Director of Craig Drill Capital, Inc., a private investment firm, and served as an operating business manager for Chubb and Son, Inc., the property and casualty insurance division of The Chubb Corporation. Mr. LeBuhn received a M.B.A. in Finance with Distinction from Columbia University Graduate School of Business in 1996. He received a B.A. in Economics from St. Lawrence University in 1988. Mr. LeBuhn currently serves as a director of Comarco, Inc.
- Louis E. Silverman
-
Louis E. Silverman，他曾一直担任私人公司Advanced ICU Care公司（医疗保健服务公司，为医院提供远程加护病房监控服务）的主席兼首席执行官。从2012年6月到2014年2月，他曾担任私人股权投资的顾问兼董事会顾问，涉及医疗技术和医疗服务组合投资。从2009年9月到2012年6月，他曾担任Marina Medical Billing Services公司（服务全国急诊科医生的收入周期管理公司）的首席执行官。此前，他曾担任高通支持医疗初创公司LifeComm的总裁兼首席执行官。从2000年8月到2008年8月，他也曾担任Quality Systems公司（医疗、牙科实践管理、病人记录软件的上市开发商）的总裁兼首席执行官。从1993年到2000年，他曾担任CorVel Corporation（上市国家管理式医疗服务科技公司）的首席运营官。他拥有Amherst College的学士学位，以及哈佛大学商学院 （ Harvard Business School ）的工商管理硕士学位。
Louis E. Silverman has served as the Chairperson and Chief Executive Officer of privately held Hicuity Health, Inc. formerly known as Advanced ICU Care, Inc., a health care services company providing remote patient monitoring services to hospitals. From June 2012 through February 2014 Mr. Silverman served as a consultant and Board advisor for private equity investors and others regarding health care technology and health care technology service companies, and health care services portfolio investments. From September 2009 through June 2012 Mr. Silverman was Chief Executive Officer of Marina Medical Billing Services, Inc., a revenue cycle management company serving ER physicians nationally. Previously, from September 2008 through August 2009 Mr. Silverman served as President and Chief Executive Officer of Qualcomm-backed health care start-up LifeComm. From August 2000 through August 2008 Mr. Silverman served as the President and Chief Executive officer of Quality Systems, Inc., a publicly traded developer of medical and dental practice management and patient records software. From 1993 through 2000 he served as Chief Operating Officer of CorVel Corporation, a publicly traded national managed care services/technology company. Mr. Silverman earned a B.A. from Amherst College and an M.B.A. from Harvard Business School. - Louis E. Silverman，他曾一直担任私人公司Advanced ICU Care公司（医疗保健服务公司，为医院提供远程加护病房监控服务）的主席兼首席执行官。从2012年6月到2014年2月，他曾担任私人股权投资的顾问兼董事会顾问，涉及医疗技术和医疗服务组合投资。从2009年9月到2012年6月，他曾担任Marina Medical Billing Services公司（服务全国急诊科医生的收入周期管理公司）的首席执行官。此前，他曾担任高通支持医疗初创公司LifeComm的总裁兼首席执行官。从2000年8月到2008年8月，他也曾担任Quality Systems公司（医疗、牙科实践管理、病人记录软件的上市开发商）的总裁兼首席执行官。从1993年到2000年，他曾担任CorVel Corporation（上市国家管理式医疗服务科技公司）的首席运营官。他拥有Amherst College的学士学位，以及哈佛大学商学院 （ Harvard Business School ）的工商管理硕士学位。
- Louis E. Silverman has served as the Chairperson and Chief Executive Officer of privately held Hicuity Health, Inc. formerly known as Advanced ICU Care, Inc., a health care services company providing remote patient monitoring services to hospitals. From June 2012 through February 2014 Mr. Silverman served as a consultant and Board advisor for private equity investors and others regarding health care technology and health care technology service companies, and health care services portfolio investments. From September 2009 through June 2012 Mr. Silverman was Chief Executive Officer of Marina Medical Billing Services, Inc., a revenue cycle management company serving ER physicians nationally. Previously, from September 2008 through August 2009 Mr. Silverman served as President and Chief Executive Officer of Qualcomm-backed health care start-up LifeComm. From August 2000 through August 2008 Mr. Silverman served as the President and Chief Executive officer of Quality Systems, Inc., a publicly traded developer of medical and dental practice management and patient records software. From 1993 through 2000 he served as Chief Operating Officer of CorVel Corporation, a publicly traded national managed care services/technology company. Mr. Silverman earned a B.A. from Amherst College and an M.B.A. from Harvard Business School.
- Arthur C. Butcher
-
暂无中文简介
暂无英文简介 -
暂无中文简介
- 暂无英文简介
- Wei Jiang
-
暂无中文简介
暂无英文简介 -
暂无中文简介
- 暂无英文简介
- Lilian Zhou
-
暂无中文简介
暂无英文简介 -
暂无中文简介
- 暂无英文简介
- Christopher Min Fang Wang
-
Christopher Min方旺是加拿大公民。
Christopher Min Fang Wang,is the founder of Yunqi Capital Limited ("Yunqi Capital") and has served as its Chief Investment Officer and portfolio manager since it was established in 2018. Before founding Yunqi Capital, Mr. Wang was a senior investment professional and Co-Portfolio Manager at Owl Creek Asia (Hong Kong) from 2008 to 2017, and prior to that served as General Manager, Corporate Finance Department of China Merchants (Holdings) International Ltd. from 2004 to 2007. Mr. Wang received a B.B.A. in Business Finance from Simon Fraser University in 1994. - Christopher Min方旺是加拿大公民。
- Christopher Min Fang Wang,is the founder of Yunqi Capital Limited ("Yunqi Capital") and has served as its Chief Investment Officer and portfolio manager since it was established in 2018. Before founding Yunqi Capital, Mr. Wang was a senior investment professional and Co-Portfolio Manager at Owl Creek Asia (Hong Kong) from 2008 to 2017, and prior to that served as General Manager, Corporate Finance Department of China Merchants (Holdings) International Ltd. from 2004 to 2007. Mr. Wang received a B.B.A. in Business Finance from Simon Fraser University in 1994.
- Neal C. Bradsher
-
Neal C. Bradsher，他是一位注册金融分析师，加入了董事会于2009年7月。自2002年以来他一直是乐活资本公司（一家私人投资公司）的总裁。他持有耶鲁大学的经济学学士学位和是一位注册金融分析师。他亦为QUESTCOR制药公司（一家生物制药公司，侧重于有严重，难以治疗自身免疫性疾病和炎症性疾病的患者的治疗）的董事。
Neal C. Bradsher,has been President of Broadwood Capital, Inc., a private investment firm, since 2002. Mr. Bradsher holds a B.A. degree in economics from Yale College and is a Chartered Financial Analyst. Mr. Bradsher was a director of Questcor Pharmaceuticals, Inc. (QCOR), from 2004 until Questcor was acquired by Mallinckrodt plc (MNK) in 2014. He has worked with several health care companies to improve their management and governance. Entities that Mr. Bradsher controls have invested in many of Lineage's financing transactions. Broadwood Capital, Inc. is the general partner of Broadwood Partners, L.P., currently Lineage Cell Therapeutics, Inc. largest shareholder. - Neal C. Bradsher，他是一位注册金融分析师，加入了董事会于2009年7月。自2002年以来他一直是乐活资本公司（一家私人投资公司）的总裁。他持有耶鲁大学的经济学学士学位和是一位注册金融分析师。他亦为QUESTCOR制药公司（一家生物制药公司，侧重于有严重，难以治疗自身免疫性疾病和炎症性疾病的患者的治疗）的董事。
- Neal C. Bradsher,has been President of Broadwood Capital, Inc., a private investment firm, since 2002. Mr. Bradsher holds a B.A. degree in economics from Yale College and is a Chartered Financial Analyst. Mr. Bradsher was a director of Questcor Pharmaceuticals, Inc. (QCOR), from 2004 until Questcor was acquired by Mallinckrodt plc (MNK) in 2014. He has worked with several health care companies to improve their management and governance. Entities that Mr. Bradsher controls have invested in many of Lineage's financing transactions. Broadwood Capital, Inc. is the general partner of Broadwood Partners, L.P., currently Lineage Cell Therapeutics, Inc. largest shareholder.
高管简历
中英对照 | 中文 | 英文- Warren Foust
- 暂无中文简介
暂无英文简介 - 暂无中文简介
- 暂无英文简介
- Magda Michna
- 暂无中文简介
暂无英文简介 - 暂无中文简介
- 暂无英文简介
- Deborah Andrews
Deborah Andrews自2013年9月起任一家上市的生物技术公司BioTime, Inc.的首席会计师，自2014年4月起任董事会和审计委员会成员，该公司专注于再生药物的新兴领域。在这之前，2005年8月至2013年9月Andrews女士曾是STAAR的副总裁兼首席财务官，她从1995年开始就在STAAR工作，2005年4月至2005年8月任STAAR财务总监，2001年至2005年任全球财务总监，1999年至2001年任STAAR Surgical AG Switzerland财务副总裁，1995年至1999年任财务总监助理。1994年至1995年她是电子元件制造商Bourns, Inc.的内部审计员，1991年至1994年是KPMG Peat Marwick的一名审计员。Andrews女士获得了圣贝纳迪诺的California State University的会计学学士学位。
Deborah Andrews,served as Chief Financial Officer of STAAR Surgical Company (STAA), a leader in the development, manufacture, and marketing of minimally invasive ophthalmic products employing proprietary technologies, from September 2017 until June 2020, after serving as Vice President, Chief Accounting Officer since 2013. Ms. Andrews also served as STAAR Surgical's Vice President, Chief Financial Officer from 2005 to 2013, as its Global Controller from 2001 to 2005, and as its Vice President, International Finance from 1999 to 2001. Ms. Andrews previously worked as a senior accountant for a major public accounting firm. Ms. Andrews holds a B.S. degree in accounting from California State University at San Bernardino.- Deborah Andrews自2013年9月起任一家上市的生物技术公司BioTime, Inc.的首席会计师，自2014年4月起任董事会和审计委员会成员，该公司专注于再生药物的新兴领域。在这之前，2005年8月至2013年9月Andrews女士曾是STAAR的副总裁兼首席财务官，她从1995年开始就在STAAR工作，2005年4月至2005年8月任STAAR财务总监，2001年至2005年任全球财务总监，1999年至2001年任STAAR Surgical AG Switzerland财务副总裁，1995年至1999年任财务总监助理。1994年至1995年她是电子元件制造商Bourns, Inc.的内部审计员，1991年至1994年是KPMG Peat Marwick的一名审计员。Andrews女士获得了圣贝纳迪诺的California State University的会计学学士学位。
- Deborah Andrews,served as Chief Financial Officer of STAAR Surgical Company (STAA), a leader in the development, manufacture, and marketing of minimally invasive ophthalmic products employing proprietary technologies, from September 2017 until June 2020, after serving as Vice President, Chief Accounting Officer since 2013. Ms. Andrews also served as STAAR Surgical's Vice President, Chief Financial Officer from 2005 to 2013, as its Global Controller from 2001 to 2005, and as its Vice President, International Finance from 1999 to 2001. Ms. Andrews previously worked as a senior accountant for a major public accounting firm. Ms. Andrews holds a B.S. degree in accounting from California State University at San Bernardino.